In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to pomalidomide (Pomalyst) and dexamethasone (Decadron) therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that adding daratumumab to pomalidomide and dexamethasone regimen reduced the risk of...
Read MoreTreatment Posts on Medivizor
What is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?
In a nutshell This study looked at the timing of chemotherapy (CT) after surgery in the treatment of early breast cancer (BC). The authors found that CT given within 31 days after surgery may improve survival in patients with triple-negative (TN) BC. Some background BC is one of the most common types of cancer found in women. There are...
Read MoreComparing lobectomy and sublobar resection for older patients with stage 1A NSCLC
In a nutshell The study was carried out to assess the difference in outcomes between lobectomy (LE) and sub-lobar resection (SLR) for older patients with stage I non-small-cell lung cancer (NSCLC). The authors found that both surgeries had similar outcomes in these patients. Some background NSCLC is responsible for 85% of lung cancer diagnoses...
Read MoreIs Ixazomib, thalidomide and dexamethasone effective in treating relapsed and/or refractory multiple myeloma?
In a nutshell This article looked at the effectiveness and safety of continuous ixazomib (Ninlaro), thalidomide (Thalomid), and dexamethasone (Decadron) (ITd) in the treatment of relapsed and/or refractory (RR) multiple myeloma (MM). The authors found that this regimen was well tolerated and showed promising effectiveness in the treatment of...
Read MoreIs pembrolizumab plus ipilimumab combination therapy safe and effective for the treatment of advanced melanoma after failure of anti-PD-1/L1 therapy?
In a nutshell This study aimed to investigate the effectiveness and safety of combining pembrolizumab (PEM; Keytruda)) and ipilimumab (IPI; Yervoy) for the treatment of advanced-stage melanoma in patients that have progressed after previous PD-1/L1 therapy. The study concluded that this combination was well tolerated and improved the...
Read MoreEvaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL
In a nutshell This study evaluated the safety and effectiveness of loncastuximab tesirine (Zynlonta) for patients with diffuse large B-cell lymphoma (DLBCL) that returned or stopped responding to treatment. This study concluded that this treatment was safe and effective for these patients. Some background DLBCL is one of the most common types of...
Read MoreEvaluating the outcomes of cotadutide treatment for patients with type 2 diabetes
In a nutshell This study evaluated the outcomes of cotadutide (MEDI0382) treatment in patients with type 2 diabetes (T2D) and obesity. This study concluded that cotadutide treatment improved glycemic (blood sugar) control and weight loss in these patients. Some background T2D is commonly associated with obesity. About 70% of patients with T2D...
Read MoreEvaluating the effectiveness of lenalidomide plus rituximab for patients with recurrent or hard-to-treat DLBCL
In a nutshell This study evaluated the safety and effectiveness of lenalidomide (Revlimid) plus rituximab (Rituxan) for patients with diffuse large B-cell lymphoma (DLBCL) that came back or stopped responding to treatment. This study concluded that this treatment showed some effectiveness, but adding other agents may improve outcomes for these...
Read MoreEvaluating CAR T-cell therapy before stem cell transplantation for patients with B-cell ALL
In a nutshell This study evaluated the safety and effectiveness of CAR T-cell therapy versus chemotherapy before a stem cell transplant (SCT) for patients with recurrent or non-responsive B-cell acute lymphoblastic lymphoma (B-ALL). The authors concluded that CAR T-cell therapy followed by SCT was safe and effective for these patients. Some background...
Read MoreComparing docetaxel to abiraterone in patients with metastatic castration-sensitive prostate cancer
In a nutshell This study compared the effectiveness of docetaxel (DOC; Taxotere) to abiraterone (ABI; Zytiga) and assessed possible predictive markers of progression-free survival (PFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The authors concluded that under real-world conditions, ABI was associated with...
Read MoreAre all glucagon-like peptide-1 receptor agonists equally safe and effective in patients with type 2 diabetes?
In a nutshell This study looked at 8 glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes (T2D). They found that all 8 were more effective than placebo and there were no significant differences in safety. Some background GLP-1RA is a type of diabetic medication that works by increasing natural...
Read MoreEffect of pioglitazone treatment in patients with prediabetes or type 2 diabetes mellitus and liver disease.
In a nutshell This study analyzed the effectiveness of pioglitazone (Actos) in patients with prediabetes or type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD). The authors concluded that pioglitazone can significantly improve liver function in these patients. Some background NAFLD is the accumulation of fat cells in the...
Read More